Status:
UNKNOWN
Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients
Lead Sponsor:
Institute for Research and Development of Medicinal and Food Plants of Guinea
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The phase II clinical trial, with three arms and at rate of 10 patients per arm, received the approval of the National Committee for Ethics and Health Research. This is a non inferiority test aimed to...
Detailed Description
The patient who has signed the informed consent for participation in the study will be immediately taken care of by the investigating clinicians. The clinician will determine the history of the diseas...
Eligibility Criteria
Inclusion
- eligible patients are symptomatic adults with COVID-19 confirmed by a positive Polymerase Chain Reaction test without complications
Exclusion
- any patient herpersensitive to hydroxychloroquine or under antimalarial treatment in the 2 weeks preceding inclusion;
- any patient with a complication who must be taken care of in an Emergency or Intensive Care Unit;
- any patient with other acute or chronic ilnesses such as heart failure, arterial hypertension, renal failure, hepatocellular failure, tuberculosis or unable to take the oral the oral treatment;
- any patient for whom one of the treatments under study is contraindicated according to the doctor's opinion;
- pregant women;
- severe neurological manifestations.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04502342
Start Date
June 1 2020
End Date
September 30 2020
Last Update
August 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Donka; Kenien; Gbessia
Conakry, Guinea, 224 Conakry